GH: Shield’s rapid scale-up, cost reductions, and broad coverage drive strong growth and market leadership
Q2 saw strong revenue and volume growth, with Shield now covering 80% of eligible patients and significant cost reductions underway. Guardant360 and Reveal platforms are expanding clinical use cases, while commercial wins and product innovation position the company for continued growth.Based on Gua…